The use of chromium-containing dietary supplements is widespread among patients with type 2 diabetes. Chromium's effects in patients at high risk for developing diabetes, especially those with metabolic syndrome, is unknown. The objective of this study was to determine the effects of chromium picolinate (CrPic) on glucose metabolism in patients with metabolic syndrome.
Method:
A double-blind, placebo-controlled, randomized trial was conducted at a U.S. academic medical center. Sixty three patients with National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III)-defined metabolic syndrome were included. The primary end point was a change in the insulin sensitivity index derived from a frequently sampled intravenous glucose tolerance test. Prespecified secondary end points included changes in other measurements of glucose metabolism, oxidative stress, fasting serum lipids, and high sensitivity C-reactive protein.
Results:
After 16 weeks of CrPic treatment, there was no significant change in insulin sensitivity index between groups (P = 0.14). However, CrPic increased acute insulin response to glucose (P = 0.02). CrPic had no significant effect on other measures of glucose metabolism, body weight, serum lipids, or measures of inflammation and oxidative stress.
Conclusion:
CrPic at 1000 μg/day does not improve key features of the metabolic syndrome in obese nondiabetic patients.
Get full access to this article
View all access options for this article.
References
1.
NBJ's Supplement Business Report 2005. Nutrition Business Journal. San Diego, CA: Penton Media, 2005.
2.
ShapiroK, GongWC. Natural products used for diabetes. J Am Pharm Assoc, 2002; 42:217–226.
3.
Expert Panel on Detection EaToHBCiA. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001; 285:2486–2497.
4.
FordES, GilesWH, DietzWH. Prevalence of the metabolic syndrome among US adults: findings From the Third National Health and Nutrition Examination Survey. JAMA, 2002; 287:356–359.
5.
FordES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care, 2005; 28:1769–1778.
6.
CefaluWT, HuFB. Role of chromium in human fealth and in diabetes. Diabetes Care, 2004; 27:2741–2751.
7.
EthanM B, TatsioniA, LichtensteinAH, LauJ, PittasAG. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized trials. Diabetes Care, 2007; 30:2154–2163.
8.
KlefstraN, HouwelingST, BakkerSJ, VerhoevenS, GansRO, JongBM, BiloH. Chromium treatment has no effect in patients with type 2 diabetes in a western population. Diabetes Care, 2007; 30:1092–1096.
9.
MartinJ, WangZQ, ZhangXH, WachtelD, VolaufovaJ, MatthewsDE, CefaluWT. Chromium picolinate supplementation attenuates body weight gain and increase insulin senistivity in subjects with type 2 diabetes. Diabetes Care, 2006; 29:1826–1832.
10.
AlthuisMD, JordanNE, LudingtonEA, WittesJT. Glucose and insulin responses to dietary chromium supplements: a meta-analysis. Am J Clin Nutr, 2002; 76:148–155.
11.
AinsworthBE, HaskellWL, WhittMI, IrwinML, SwartzAM, StrathSJ, O'BrienWL, BassettDRJr, SchmitzKHet al.Compendium of physical activities: and update of activity codes and MET intensities. Med Sci Sports Exerc, 2000; 32:s498–516.
12.
BernsteinM, SloutskisD, KumanyikaS, SpartiA, SchutzY, MorabiaA. Data-based approach for developing a physical activity frequency questionnaire. Am J Epidemiol, 1998; 147:147–154.
13.
BergmanR, IderY, BowdenC, CobelliC. Quantitative estimation of insulin sensitivity. Am J Physiol, 1979; 236:E667–E677.
14.
BostonR, StefanovskiD, MoateP, SumnerAE, WatanabeRM, BergmanR. MINMOD Millenium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Therapeut, 2003; 5:1003–1015.
15.
LawsonJ, LiH, RokachJ, AdiyamanM, HwangSW, KhanapureSP, FitzGeraldGA. Identification of two major F2 isoprostanes 8, 12-iso-and 5-epi-8, 12-iso-isoprostane F2a-VI in human urine. J Biol Chem, 1998; 273:29295–29301.
16.
AndersonR, PolanskyMM, BrydenNA, PattersonKY, VeillonC, GlinsmannWH. Effects of chromium supplementation on urinary Cr excretion of human subjects and correlation of Cr excretion with selected clinical parameters. J Nutrit, 1983; 113:276–281.
17.
PotterJ, LevinP, AndersonR, FreibergJ, AndresR, ElahiD. Glucose metabolism in glucose-intolerant older people during chromium supplementation. Metabolism, 1985; 34:199–204.
18.
CefaluWT, Bell-FarrowAD, StegnerJ, WangZQ, KingT, TerryJG. Effect of chromium picolinate on insulin sensitivity in vivo. J Trace Elements Exp Med, 1999; 12:71–83.
19.
AmatoP, MoralesAJ, YenSSC. Effects of chromium picolinate xupplementation on insulin sensitivity, serum lipids, and body composition in healthy, nonobese, older men and women. J Gerontol A Biol Sci Med Sci, 2000; 55:M260–M263.
20.
GuntonJE, CheungNW, HitchmanR, HamsG, O'SullivanC, Foster-PowellK, McElduffA. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care, 2005; 28:712–713.
21.
WilsonB, GondyA. Effects of chromium supplementation on fasting insulin levels and lipid parameters in healthy, nonobese young subjects. Diabetes Res Clin Pract, 1995; 28:179–184.
22.
AndersonRA, ChengN, BrydenNA, PolanskyMM, ChengN, ChiJ, FengJ. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes, 1997; 46:1786–1791.
23.
JosephLJO, FarrellPA, DaveySL, EvansWJ, CampbellWW. Effect of resistance training with or without chromium picolinate supplementation on glucose metabolism in older men and women. Metabolism, 1999; 48:546–553.
24.
BostonR, MoateP, StefanovskiD, SumnerAE, BergmanRN. AKA-Glucose: a program for kinetic and epidemiological analysis of frequently sampled intravenous glucose tolerance test data using database technology. Diabetes Technol Therapeut, 2005; 7:298–307.
25.
HanleyAJG, D'AgostinoRJr, WagenknechtLE, SaadMF, SavagePJ, BergmanR, HaffnerSM. Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes, 2002; 51:1263–1270.
26.
Novartis announces largest diabetes cardiovascular disease prevention trial with Starlix Diovan. Novartis Pharmaceuticals USA, 20062-22-2006http://www.pharma.us.novartis.com/newsroom/pressReleases/releaseDetail.jsp?PRID=141/.
27.
PittlerM, StevinsonC, ErnstE. Chromium picolinate for reducing body weight: Meta-analysis of randomized trials. Int J Obesity, 2003; 27:522–529.
28.
PressR, GellerJ, EvansG. The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects. West J Med, 1990; 152:41–45.
29.
VincentJB. Recent advances in the nutritional biochemistry of trivalent chromium. Proc Nutr Soc, 2004; 63:41–47
WasserWG, FeldmanNS, D'AgatiVD. Chronic renal failure after ingestion of over-the-counter chromium picolinate. Ann Intern Med, 1997; 126:410.
32.
WilsonB, GondyA. Effects of chromium supplementation on fasting insulin levels and lipid parameters in healthy, nonobese young subjects. Diabetes Res Clin Pract, 1995; 28:179–184.
